The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Mylan is known for making good quality, reliable generic pharmaceutical products, but I think their primary drawback is they haven't found a way to outcompete the generic market. In the pharmacy, cheaper generics are preferred to Mylan's oftentimes more expensive products. Teva and Dr. Reddy are two companies, even though their tablets crumble to the touch, will always beat Mylan out of the inventory at CVS or Walgreens.
Look for a test of $12 support...the long term growth potential is priced in and Obama's national health care ambitions will bring regulatory and price control volatility along with the retail movement due to the new market cap/growth prospects. Be patient, don't chase!